1887

oa Current Allergy & Clinical Immunology - Introducing NeXomist - : product news

Volume 23, Issue 3
  • ISSN : 1609-3607

 

Abstract

Healthcare professionals globally rely on mometasone for the treatment of allergic rhinitis. With characteristics such as lowest systemic bioavailability, significant relief within 12 hours, most lipophilic molecule, high affinity for the glucocorticoid receptor and safety in children from 2 years of age, we understand why. Cipla is now offering this molecule to all your patients at a significant reduction in cost.

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/caci/23/3/EJC21664
2010-08-01
2019-10-15

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error